Journal article
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer
Abstract
Preclinical studies demonstrate that intratumoral delivery of adenovirus expressing IL-2 eradicates pre-established tumors in mice and confers immune protection from rechallenge. To explore the activity of AdCAIL-2 in prostate cancer, a Phase I clinical trial was conducted in patients with localized disease and Gleason score >7 or prostate-specific antigen (PSA) >10 plus Gleason score 7. A total of 12 patients were injected 4 weeks prior to …
Authors
Trudel S; Trachtenberg J; Toi A; Sweet J; Hua Li Z; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y
Journal
Cancer Gene Therapy, Vol. 10, No. 10, pp. 755–763
Publisher
Springer Nature
Publication Date
October 1, 2003
DOI
10.1038/sj.cgt.7700626
ISSN
0929-1903